Interleukin-6 and platelet protagonists in T lymphocyte and virological response

Maria Jose Miguez, Allan E Rodriguez, Sonya Hadrigan, Deshratn Asthana, Ximena Burbano, Mary Ann Fletcher

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The present cross-sectional study evaluated the status and relationship of interleukin-6, a platelet growth factor, with platelet counts, viral load, CD4 counts, and antiretroviral treatment in 75 HIV-infected subjects with thrombocytopenia and 50 gender-, race-, age- and antiretroviral treatment-matched controls without thrombocytopenia. Mean IL-6 production was significantly higher in thrombocytopenic participants (13 432 ± 8596) than in non-thrombocytopenic subjects (12 859 ± 3538 pg/105 Lym). Univariate analyses indicated, however, that thrombocytopenic patients were more likely to have <3000 pg of IL-6 than non-thrombocytopenic patients (OR = 7 95% CI 1.3-12; P = 0.01). For additional analyses, participants were dichotomized above and below 3000 pg of IL-6. Despite similar age, gender, drug use and antiretroviral treatment, thrombocytopenic participants had lower CD4 counts (186.5 ± 149 vs. 401 ± 286, P = 0.005) than non-thrombocytopenic subjects. Thrombocytopenic participants with elevated IL-6, with or without HAART, were more likely to have higher HIV-replication (496 273 ± 210 416; 34 656 ± 25 332) than thrombocytopenic individuals with low IL-6 levels (105 332 ± 42 699; 19 015 ± 14 296 P = 0.05). Non-thrombocytopenic patients with high IL-6 levels exhibited the highest CD4s (466.7 ± 333) and the lowest viral burden (63 094 ± 53 300) of the groups. Two distinct categories of HIV-associated thrombocytopenia exist: one accompanied by low IL-6, and another with compensatory elevations of IL-6. In thrombocytopenic individuals, the latter was associated with the poorest immunological and virological responses.

Original languageEnglish
Pages (from-to)281-286
Number of pages6
JournalPlatelets
Volume16
Issue number5
DOIs
StatePublished - Aug 1 2005

Fingerprint

Interleukin-6
Blood Platelets
T-Lymphocytes
Thrombocytopenia
HIV
CD4 Lymphocyte Count
Viral Load
Highly Active Antiretroviral Therapy
Platelet Count
Intercellular Signaling Peptides and Proteins
Therapeutics
Cross-Sectional Studies
Pharmaceutical Preparations

Keywords

  • CD4
  • IL-6
  • Platelets
  • Viral load

ASJC Scopus subject areas

  • Hematology
  • Cell Biology

Cite this

Miguez, M. J., Rodriguez, A. E., Hadrigan, S., Asthana, D., Burbano, X., & Fletcher, M. A. (2005). Interleukin-6 and platelet protagonists in T lymphocyte and virological response. Platelets, 16(5), 281-286. https://doi.org/10.1080/09537100400028727

Interleukin-6 and platelet protagonists in T lymphocyte and virological response. / Miguez, Maria Jose; Rodriguez, Allan E; Hadrigan, Sonya; Asthana, Deshratn; Burbano, Ximena; Fletcher, Mary Ann.

In: Platelets, Vol. 16, No. 5, 01.08.2005, p. 281-286.

Research output: Contribution to journalArticle

Miguez, MJ, Rodriguez, AE, Hadrigan, S, Asthana, D, Burbano, X & Fletcher, MA 2005, 'Interleukin-6 and platelet protagonists in T lymphocyte and virological response', Platelets, vol. 16, no. 5, pp. 281-286. https://doi.org/10.1080/09537100400028727
Miguez, Maria Jose ; Rodriguez, Allan E ; Hadrigan, Sonya ; Asthana, Deshratn ; Burbano, Ximena ; Fletcher, Mary Ann. / Interleukin-6 and platelet protagonists in T lymphocyte and virological response. In: Platelets. 2005 ; Vol. 16, No. 5. pp. 281-286.
@article{27e75629b5594902b1dd985f7d633cf1,
title = "Interleukin-6 and platelet protagonists in T lymphocyte and virological response",
abstract = "The present cross-sectional study evaluated the status and relationship of interleukin-6, a platelet growth factor, with platelet counts, viral load, CD4 counts, and antiretroviral treatment in 75 HIV-infected subjects with thrombocytopenia and 50 gender-, race-, age- and antiretroviral treatment-matched controls without thrombocytopenia. Mean IL-6 production was significantly higher in thrombocytopenic participants (13 432 ± 8596) than in non-thrombocytopenic subjects (12 859 ± 3538 pg/105 Lym). Univariate analyses indicated, however, that thrombocytopenic patients were more likely to have <3000 pg of IL-6 than non-thrombocytopenic patients (OR = 7 95{\%} CI 1.3-12; P = 0.01). For additional analyses, participants were dichotomized above and below 3000 pg of IL-6. Despite similar age, gender, drug use and antiretroviral treatment, thrombocytopenic participants had lower CD4 counts (186.5 ± 149 vs. 401 ± 286, P = 0.005) than non-thrombocytopenic subjects. Thrombocytopenic participants with elevated IL-6, with or without HAART, were more likely to have higher HIV-replication (496 273 ± 210 416; 34 656 ± 25 332) than thrombocytopenic individuals with low IL-6 levels (105 332 ± 42 699; 19 015 ± 14 296 P = 0.05). Non-thrombocytopenic patients with high IL-6 levels exhibited the highest CD4s (466.7 ± 333) and the lowest viral burden (63 094 ± 53 300) of the groups. Two distinct categories of HIV-associated thrombocytopenia exist: one accompanied by low IL-6, and another with compensatory elevations of IL-6. In thrombocytopenic individuals, the latter was associated with the poorest immunological and virological responses.",
keywords = "CD4, IL-6, Platelets, Viral load",
author = "Miguez, {Maria Jose} and Rodriguez, {Allan E} and Sonya Hadrigan and Deshratn Asthana and Ximena Burbano and Fletcher, {Mary Ann}",
year = "2005",
month = "8",
day = "1",
doi = "10.1080/09537100400028727",
language = "English",
volume = "16",
pages = "281--286",
journal = "Platelets",
issn = "0953-7104",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Interleukin-6 and platelet protagonists in T lymphocyte and virological response

AU - Miguez, Maria Jose

AU - Rodriguez, Allan E

AU - Hadrigan, Sonya

AU - Asthana, Deshratn

AU - Burbano, Ximena

AU - Fletcher, Mary Ann

PY - 2005/8/1

Y1 - 2005/8/1

N2 - The present cross-sectional study evaluated the status and relationship of interleukin-6, a platelet growth factor, with platelet counts, viral load, CD4 counts, and antiretroviral treatment in 75 HIV-infected subjects with thrombocytopenia and 50 gender-, race-, age- and antiretroviral treatment-matched controls without thrombocytopenia. Mean IL-6 production was significantly higher in thrombocytopenic participants (13 432 ± 8596) than in non-thrombocytopenic subjects (12 859 ± 3538 pg/105 Lym). Univariate analyses indicated, however, that thrombocytopenic patients were more likely to have <3000 pg of IL-6 than non-thrombocytopenic patients (OR = 7 95% CI 1.3-12; P = 0.01). For additional analyses, participants were dichotomized above and below 3000 pg of IL-6. Despite similar age, gender, drug use and antiretroviral treatment, thrombocytopenic participants had lower CD4 counts (186.5 ± 149 vs. 401 ± 286, P = 0.005) than non-thrombocytopenic subjects. Thrombocytopenic participants with elevated IL-6, with or without HAART, were more likely to have higher HIV-replication (496 273 ± 210 416; 34 656 ± 25 332) than thrombocytopenic individuals with low IL-6 levels (105 332 ± 42 699; 19 015 ± 14 296 P = 0.05). Non-thrombocytopenic patients with high IL-6 levels exhibited the highest CD4s (466.7 ± 333) and the lowest viral burden (63 094 ± 53 300) of the groups. Two distinct categories of HIV-associated thrombocytopenia exist: one accompanied by low IL-6, and another with compensatory elevations of IL-6. In thrombocytopenic individuals, the latter was associated with the poorest immunological and virological responses.

AB - The present cross-sectional study evaluated the status and relationship of interleukin-6, a platelet growth factor, with platelet counts, viral load, CD4 counts, and antiretroviral treatment in 75 HIV-infected subjects with thrombocytopenia and 50 gender-, race-, age- and antiretroviral treatment-matched controls without thrombocytopenia. Mean IL-6 production was significantly higher in thrombocytopenic participants (13 432 ± 8596) than in non-thrombocytopenic subjects (12 859 ± 3538 pg/105 Lym). Univariate analyses indicated, however, that thrombocytopenic patients were more likely to have <3000 pg of IL-6 than non-thrombocytopenic patients (OR = 7 95% CI 1.3-12; P = 0.01). For additional analyses, participants were dichotomized above and below 3000 pg of IL-6. Despite similar age, gender, drug use and antiretroviral treatment, thrombocytopenic participants had lower CD4 counts (186.5 ± 149 vs. 401 ± 286, P = 0.005) than non-thrombocytopenic subjects. Thrombocytopenic participants with elevated IL-6, with or without HAART, were more likely to have higher HIV-replication (496 273 ± 210 416; 34 656 ± 25 332) than thrombocytopenic individuals with low IL-6 levels (105 332 ± 42 699; 19 015 ± 14 296 P = 0.05). Non-thrombocytopenic patients with high IL-6 levels exhibited the highest CD4s (466.7 ± 333) and the lowest viral burden (63 094 ± 53 300) of the groups. Two distinct categories of HIV-associated thrombocytopenia exist: one accompanied by low IL-6, and another with compensatory elevations of IL-6. In thrombocytopenic individuals, the latter was associated with the poorest immunological and virological responses.

KW - CD4

KW - IL-6

KW - Platelets

KW - Viral load

UR - http://www.scopus.com/inward/record.url?scp=21744451148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21744451148&partnerID=8YFLogxK

U2 - 10.1080/09537100400028727

DO - 10.1080/09537100400028727

M3 - Article

C2 - 16011978

AN - SCOPUS:21744451148

VL - 16

SP - 281

EP - 286

JO - Platelets

JF - Platelets

SN - 0953-7104

IS - 5

ER -